|
1
|
Parsons SL, Watson SA and Steele RJ:
Malignant ascites. Br J Surg. 83:6–14. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Runyon BA: Care of patients with ascites.
N Engl J Med. 330:337–342. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sasako M: Principles of surgical treatment
for curable gastric cancer. J Clin Oncol. 21 23 Suppl:274s–275s.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Becker G, Galandi D and Blum HE: Malignant
ascite: Systematic review and guideline for treatment. Eur J
Cancer. 42:589–597. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Smith EM and Jayson GC: The current and
future management of malignant ascites. Clin Oncol (R Coll Radiol).
15:59–72. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cruciani RA, Barker JL, Zasloff M, Chen HC
and Colamonici O: Antibiotic magainins exert cytolytic activity
against transformed cell lines through channel formation. Proc Natl
Acad Sci USA. 88:pp. 3792–3796. 1991; View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jin XB, Li XB, Zhu JY, Lu XM, Shen J, Chu
FJ and Mei HF: The target of Musca domestica cecropin on human
hepatocellular carcinoma BEL-7402 cells. Zhongguo Ji Sheng Chong
Xue Yu Ji Sheng Chong Bing Za Zhi. 29:271–273. 2011.(In Chinese).
PubMed/NCBI
|
|
8
|
Jin XB, Wang YJ, Liang LL, Pu QH, Shen J,
Lu XM, Chu FJ and Zhu JY: Cecropin suppresses human hepatocellular
carcinoma BEL-7402 cell growth and survival in vivo without
side-toxicity. Asian Pac J Cancer Prev. 15:5433–5436. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu Z, Zhang F, Cai L, Zhao G and Wang B:
Studies on the properties of cecropin-XJ expressed in yeast from
Xinjiang silkworm. Wei Sheng Wu Xue Bao. 43:635–641. 2003.(In
Chinese). PubMed/NCBI
|
|
10
|
Xia L, Zhang F, Liu Z, Ma J and Yang J:
Expression and characterization of cecropinXJ, a bioactive
antimicrobial peptide from Bombyx mori (Bombycidae,
Lepidoptera) in Escherichia coli. Exp Ther Med.
5:1745–1751. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xia L, Liu Z, Ma J, Sun S, Yang J and
Zhang F: Expression, purification and characterization of cecropin
antibacterial peptide from Bombyx mori in Saccharomyces
cerevisiae. Protein Expr Purif. 90:47–54. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wu YL, Xia LJ, Li JY and Zhang FC:
CecropinXJ inhibits the proliferation of human gastric cancer
BGC823 cells and induces cell death in vitro and in vivo. Int J
Oncol. 46:2181–2193. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xia L, Wu Y, Kang S, Ma J, Yang J and
Zhang F: CecropinXJ, a silkworm antimicrobial peptide, induces
cytoskeleton disruption in esophageal carcinoma cells. Acta Biochim
Biophys Sin (Shanghai). 46:867–876. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wu Y, Xia L and Zhang F: Inhibition of
CecropinXJ on proliferation of human gastric cancer AGS cells. Chin
J Cell Biol. 36:1355–1361. 2014.(In Chinese).
|
|
15
|
Fung KY, Ooi CC, Zucker MH, Lockett T,
Williams DB, Cosgrove LJ and Topping DL: Colorectal carcinogenesis:
A cellular response to sustained risk environment. Int J Mol Sci.
14:13525–13541. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lettre H: Tests of compounds against the
Ehrlich mouse ascites tumor. Cancer Res. 2 Suppl:S125–S128.
1955.
|
|
17
|
Sugiura K: Effect of various compounds on
the Ehrlich ascites carcinoma. Cancer Res. 13:431–441.
1953.PubMed/NCBI
|
|
18
|
Dagistan Y, Dagistan E and Citisli V:
Evaluation of simple blood counts as inflammation markers for brain
tumor patients. Neurol Neurochir Pol. 50:231–235. 2016.PubMed/NCBI
|
|
19
|
Sedláková O, Sedlák J, Hunáková L,
Jakubíková J, Duraj J, Sulíková M, Chovancová J and Chorváth B:
Angiogenesis inhibitor TNP-470: Cytotoxic effects on human
neoplastic cell lines. Neoplasma. 46:283–289. 1999.PubMed/NCBI
|
|
20
|
Yoshizawa J, Mizuno R, Yoshida T, Hara A,
Ashizuka S, Kanai M, Kuwashima N, Kurobe M and Yamazaki Y:
Inhibitory effect of TNP-470 on hepatic metastasis of mouse
neuroblastoma. J Surg Res. 93:82–87. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Oey RC, van Buuren HR and de Man RA: The
diagnostic work-up in patients with ascites: Current guidelines and
future prospects. Neth J Med. 74:330–335. 2016.PubMed/NCBI
|
|
22
|
Sostelly A, Henin E, Chauvenet L,
Hardy-Bessard AC, Jestin-Le Tallec V, Kirsher S, Leyronnas C,
Ligeza-Poisson C, Ramdane S, Salavt J, et al: Can we predict
chemo-induced hematotoxicity in elderly patients treated with
pegylated liposomal doxorubicin? Results of a population-based
model derived from the DOGMES phase II trial of the GINECO. J
Geriatr Oncol. 4:48–57. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zolfagharzadeh F and Roshan VD:
Pretreatment hepatoprotective effect of regular aerobic training
against hepatic toxicity induced by Doxorubicin in rats. Asian Pac
J Cancer Prev. 14:2931–2936. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hogland HC: Hematologic complications of
cancer chemotherapy. Semin Oncol. 9:95–102. 1982.PubMed/NCBI
|
|
25
|
Arora S, Jain J, Rajwade JM and Paknikar
KM: Cellular responses induced by silver nanoparticles: In vitro
studies. Toxicol Lett. 179:93–100. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Maseki M, Nishigaki I, Hagihara M, Tomoda
Y and Yagi K: Lipid peroxide levels and lipids content of serum
lipoprotein fractions of pregnant subjects with or without
pre-eclampsia. Clin Chim Acta. 115:155–161. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Verhaeghe L, Bruyneel L, Stragier E,
Ferrante M, Dierickx D and Prenen H: The effectiveness of
intravenous iron for iron deficiency anemia in gastrointestinal
cancer patients: A retrospective study. Ann Gastroenterol.
30:654–663. 2017.PubMed/NCBI
|
|
28
|
Dong JF, Zheng XQ and Rui HB: Effect of
taurine on immune function in mice with T-cell lymphoma during
chemotherapy. Asian Pac J Trop Med. 10:1090–1094. 2017. View Article : Google Scholar : PubMed/NCBI
|
